Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 481–504 of 7,238 matching trials from the live ClinicalTrials.gov search.
Filters: Detroit, Michigan Clear all
Completed Not applicable Interventional

Motivational Enhancement System for Adherence (MESA) for Youth Starting ART

NCT02761746
View directory record Official record
Conditions
Medication Adherence
Interventions
MESA
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
16 Years to 24 Years
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
7
States / cities
Los Angeles, California • Aurora, Colorado • Washington D.C., District of Columbia + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 30, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

Amplitude-Modulated Radiofrequency Electromagnetic Fields (AM RF EMF) in Combination With Fruquintinib in Refractory Metastatic Colorectal Cancer

NCT07130903
View directory record Official record
Conditions
Metastatic Colorectal Adenocarcinoma
Interventions
Fruquintinib, TheraBionic P1
Drug · Device
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
22 Years and older
Enrollment
102 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
9
States / cities
Bay City, Michigan • Clarkston, Michigan • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Recruiting Not applicable Interventional

Radial vs. State-Of-The-Art Femoral Access for Bleeding and Access Site Complication Reduction in Cardiac Catheterization (REBIRTH)

NCT04077762
View directory record Official record
Conditions
Patient Satisfaction, Vascular Access Complication
Interventions
Radial Access, State-of-the-art femoral access with 18 gauge needle, State-of-the-art femoral access with 21 gauge needle
Procedure
Lead sponsor
Minneapolis Heart Institute Foundation
Other
Eligibility
18 Years and older
Enrollment
3,266 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2028
U.S. locations
6
States / cities
San Francisco, California • Jacksonville, Florida • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Study to Assess Safety of AZD7762 Administered Alone and in Combination With Gemcitabine in Patients With Advanced Solid Malignancies

NCT00413686
View directory record Official record
Conditions
Solid Tumors
Interventions
AZD7762, Gemcitabine
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
2
States / cities
Baltimore, Maryland • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Dec 6, 2010 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

Minimally Invasive Surgery Plus Rt-PA for ICH Evacuation Phase III

NCT01827046
View directory record Official record
Conditions
Intracerebral Hemorrhage
Interventions
rt-PA
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
499 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
56
States / cities
Birmingham, Alabama • Phoenix, Arizona • Carmichael, California + 46 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2019 · Synced Oct 30, 2026, 1:38 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

NCT04404283
View directory record Official record
Conditions
Diffuse Large B-cell Lymphoma
Interventions
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Drug · Other
Lead sponsor
Seagen, a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
47
States / cities
Birmingham, Alabama • Sacramento, California • Bonita Springs, Florida + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 21, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study Assessing Pamiparib With Radiation and/or Temozolomide (TMZ) in Participants With Newly Diagnosed or Recurrent Glioblastoma

NCT03150862
View directory record Official record
Conditions
Brain and Central Nervous System Tumors
Interventions
Pamiparib, TMZ, Radiation
Drug · Radiation
Lead sponsor
BeiGene USA, Inc.
Industry
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
18
States / cities
Tucson, Arizona • Los Angeles, California • San Francisco, California + 14 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 1Phase 2 Interventional

Efficacy and Safety of AEB071 Versus Tacrolimus in Combination With Mycophenolate Acid Sodium, Basiliximab and Steroids in Preventing Acute Rejection After Kidney Transplantation

NCT00492869
View directory record Official record
Conditions
Kidney Transplantation
Interventions
AEB071
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
124 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2007
U.S. locations
23
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2020 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 2 Interventional Results available

Study of Intratumoral (IT) Ulevostinag (MK-1454) in Combination With Intravenous (IV) Pembrolizumab (MK-3475) Compared to IV Pembrolizumab Alone as the First Line Treatment of Metastatic or Unresectable, Recurrent Head and Neck Squamous Cell Carcinoma (HNSCC) (MK-1454-002)

NCT04220866
View directory record Official record
Conditions
Head and Neck Squamous Cell Carcinoma (HNSCC)
Interventions
Ulevostinag, Pembrolizumab
Drug · Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
6
States / cities
Los Angeles, California • San Francisco, California • Detroit, Michigan + 3 more
Source: ClinicalTrials.gov public record
Updated Oct 29, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

LUMINA Phase III Study Assessing the Efficacy and Safety of Intravitreal Injections of 440 ug DE-109 Sirolimus for the Treatment of Active, Non-Infectious Uveitis of the Posterior Segment of the Eye

NCT03711929
View directory record Official record
Conditions
Non Infectious Uveitis
Interventions
DE-109 Intravitreal Injections, Sham Procedure, DE-109 Intravitreal Injections (Open Label)
Drug · Other
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
38
States / cities
Phoenix, Arizona • Beverly Hills, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2023 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 1 Interventional

Dose Escalation Study of mRNA-2752 for Intratumoral Injection to Participants in Advanced Malignancies

NCT03739931
View directory record Official record
Conditions
Dose Escalation: Relapsed/Refractory Solid Tumor Malignancies or Lymphoma, Dose Expansion: Triple Negative Breast Cancer, HNSCC, Non-Hodgkins, Urothelial Cancer, Immune Checkpoint Refractory Melanoma, and NSCLC Lymphoma
Interventions
mRNA-2752, Durvalumab
Biological
Lead sponsor
ModernaTX, Inc.
Industry
Eligibility
18 Years and older
Enrollment
134 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
16
States / cities
San Francisco, California • Santa Monica, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 15, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 3 Interventional Results available

S0521, Combination Chemotherapy With or Without Gemtuzumab Followed By Tretinoin, Mercaptopurine, and Methotrexate or Observation in Treating Patients With Acute Promyelocytic Leukemia

NCT00492856
View directory record Official record
Conditions
Leukemia
Interventions
mercaptopurine, methotrexate, tretinoin
Drug
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 120 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2016
U.S. locations
210
States / cities
Scottsdale, Arizona • Roseville, California • Sacramento, California + 135 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2023 · Synced Oct 30, 2026, 1:38 PM EDT
Active, not recruiting Phase 2Phase 3 Interventional

Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

NCT03117751
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
Interventions
Prednisone, Vincristine, Daunorubicin, Pegaspargase, Erwinase®, Cyclophosphamide, Cytarabine, Mercaptopurine, Dasatinib, Methotrexate, Blinatumomab, Ruxolitinib, Bortezomib, Dexamethasone, Doxorubicin, Etoposide, Clofarabine, Vorinostat, Idarubicin, Nelarabine, Thioguanine, Asparaginase Erwinia chrysanthemi (recombinant)-rywn, Calaspargase Pegol
Drug
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
1 Year to 18 Years
Enrollment
790 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2028
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Peoria, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Suspended Phase 2Phase 3 Interventional

Safety and Efficacy of Talactoferrin Alfa in Patients With Severe Sepsis

NCT01273779
View directory record Official record
Conditions
Severe Sepsis
Interventions
Talactoferrin alfa, Placebo
Drug
Lead sponsor
Agennix
Industry
Eligibility
18 Years and older
Enrollment
1,280 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
34
States / cities
Birmingham, Alabama • Mobile, Alabama • Maricopa, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2012 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Clinical and Economic Outcomes of Ceftaroline Fosamil for ABSSSI Documented or at Risk of MRSA

NCT02582203
View directory record Official record
Conditions
Skin Diseases, Infectious, Staphylococcal Skin Infections
Interventions
Ceftaroline, Vancomycin
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 89 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2016
U.S. locations
3
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 30, 2026, 1:38 PM EDT
Completed No phase listed Observational Results available

Physical Therapy and Occupational Therapy After Transcatheter Aortic Valve Replacement

NCT03117296
View directory record Official record
Conditions
Transcatheter Aortic Valve Implantation
Interventions
Post procedure daily PT and OT, PT post procedure, OT post procedure, Routine PT or OT
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
Not listed
Enrollment
189 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 20, 2023 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Not applicable Interventional

Increasing Effectiveness of an Alcohol Use Reduction Exercise Using Self-Talk Videos

NCT06593483
View directory record Official record
Conditions
Heavy Drinking
Interventions
Motivational Interview with Self-Talk Video, Motivational Interviewing
Behavioral
Lead sponsor
Wayne State University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 10, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Recruiting Phase 2 Interventional

A Randomized Controlled Phase II Trial of STIMULAN VG vs Standard of Care (SoC) for the Treatment of Osteomyelitis Associated With Stage IV Pressure Ulcers.

NCT06283979
View directory record Official record
Conditions
Pressure Ulcer, Stage IV, Osteomyelitis
Interventions
STIMULAN VG, Standard of Care
Combination Product · Procedure
Lead sponsor
Biocomposites Ltd
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
9
States / cities
Phoenix, Arizona • Chicago, Illinois • Detroit, Michigan + 6 more
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Terminated Phase 1 Interventional

Partial Brain RT, Temozolomide, Chloroquine, and TTF Therapy for the Treatment of Newly Diagnosed Glioblastoma

NCT04397679
View directory record Official record
Conditions
Glioblastoma, Gliosarcoma
Interventions
3-Dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy (IMRT), Temozolomide, Chloroquine, Tumor Treating Fields Therapy (TTF)
Radiation · Drug · Procedure
Lead sponsor
Barbara Ann Karmanos Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 30, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

ROSETTA Breast-01: The Effects and Safety of Pumitamig in Patients With Triple-Negative Breast Cancer

NCT07173751
View directory record Official record
Conditions
Breast Neoplasms
Interventions
Pumitamig, Nab-paclitaxel/Paclitaxel, Gemcitabine, Carboplatin, Eribulin, Matching placebo
Drug
Lead sponsor
BioNTech SE
Industry
Eligibility
18 Years and older
Enrollment
558 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
71
States / cities
Springdale, Arkansas • La Jolla, California • Los Alamitos, California + 56 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Completed No phase listed Observational

Natural Progression of High-Risk Chronic Limb-Threatening Ischemia: The CLariTI Study

NCT04304105
View directory record Official record
Conditions
Critical Limb Ischemia, Peripheral Artery Disease
Interventions
Not listed
Lead sponsor
LimFlow, Inc.
Industry
Eligibility
18 Years and older
Enrollment
192 participants
Timeline
2020 – 2022
U.S. locations
24
States / cities
Los Angeles, California • Torrance, California • Denver, Colorado + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2024 · Synced Oct 30, 2026, 1:38 PM EDT
Recruiting Phase 3 Interventional

Anticoagulation in ICH Survivors for Stroke Prevention and Recovery

NCT03907046
View directory record Official record
Conditions
Intracerebral Hemorrhage, Atrial Fibrillation
Interventions
Apixaban, Aspirin
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
700 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
186
States / cities
Birmingham, Alabama • Mobile, Alabama • Chandler, Arizona + 141 more
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 1:38 PM EDT
Completed Phase 2 Interventional

Comparison of Stavudine Used Alone or in Combination With Didanosine in HIV-Infected Children

NCT00000851
View directory record Official record
Conditions
HIV Infections
Interventions
Stavudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
6 Months to 10 Years
Enrollment
198 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1998
U.S. locations
32
States / cities
Torrance, California • Aurora, Colorado • Farmington, Connecticut + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 4, 2021 · Synced Oct 30, 2026, 1:38 PM EDT
Terminated Phase 3 Interventional Results available

Study of Ruxolitinib in Pancreatic Cancer Patients (Janus 1)

NCT02117479
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Ruxolitinib, Placebo, Capecitabine
Drug
Lead sponsor
Incyte Corporation
Industry
Eligibility
18 Years and older
Enrollment
321 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
153
States / cities
Avondale, Arizona • Chandler, Arizona • Gilbert, Arizona + 150 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2019 · Synced Oct 30, 2026, 1:38 PM EDT